Израел - Хебрејски - Ministry of Health

teva pharmaceutical industries ltd, israel - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Израел - Хебрејски - Ministry of Health

teva israel ltd - pravastatin sodium - טבליה - pravastatin sodium 40 mg - hmg coa reductase inhibitors - pravastatin is indicated as a component of multiple risk factor intervention in those individuals at increased risk for atherosclerotic vascular disease due to hypercholesterolemia . pravastatin should be used in addition to a diet restricted in saturated fat and cholesterol when the response to diet and other nonpharmacological measures alone has been inadequate. *primary prevention of coronary events: in hypercholesterolemic patients whthout clinically evident coronary heart disease pravastatin is indicated to: - reduce the risk of myocardial infarcton. - reduce the risk for revascularization. - reduce the risk of deaths due to cardiovascular causes with no increase in deaths from non-cardiovascular causes. *secondary prevention of cardiovascular events: atherosclerosis: in hypercholesterolemic patients with clinically evident coronary artery disease including prior mi pravastatin is indicated to: - slow the progression of coronary atherosclerosis. - reduce the risk of acute coronary events. myocardial infa

Израел - Хебрејски - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 1500 iu / 4 ml - coagulation factor viii

Израел - Хебрејски - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 250 iu / 4 ml - coagulation factor viii

Израел - Хебрејски - Ministry of Health

novo nordisk ltd, israel - turoctocog alfa - אבקה וממס להכנת תמיסה להזרקה - turoctocog alfa 3000 iu / 4 ml - coagulation factor viii

Израел - Хебрејски - Ministry of Health

novartis israel ltd - secukinumab - תמיסה להזרקה - secukinumab 150 mg/ml - secukinumab

Израел - Хебрејски - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations

Израел - Хебрејски - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 6.14 mg; trifluridine 15 mg - trifluridine, combinations

Израел - Хебрејски - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations

Израел - Хебрејски - Ministry of Health

medison pharma ltd - tipiracil as hydrochloride; trifluridine - טבליות מצופות פילם - tipiracil as hydrochloride 8.19 mg; trifluridine 20 mg - trifluridine, combinations